We can do it! Improving access to care for transgender and gender diverse patients

We can do it! Improving access to care for transgender and gender diverse patients

Compared with the general population, transgender and gender diverse people are more likely to experience poor health outcomes, such as chronic health conditions, HIV, substance use, and mental illness. We know these disparities are due structural factors, such as political and economic policies, and interpersonal factors, such as discrimination, stigma, and violence. Transgender people are also more likely to encounter barriers to accessing health insurance and health care. When transgender people do access health care, nearly half report being mistreated by medical providers.

In this episode, Dr. Antonio E. Urbina, Medical Director of CEI’s HIV Primary Care and Prevention Center of Excellence, speaks with Dr. Joshua D. Safer, Executive Director of Mount Sinai’s Center for Transgender Medicine (CTMS) and Professor at the Icahn School of Medicine. While gender wellness clinics like CTMS are so important, there is a need to expand the health care workforce of providers treating transgender patients. For example, transgender patients report barriers to accessing inclusive primary care providers and specialists who can treat them outside of their gender-affirming interventions. Drs. Urbina and Safer unpack common misconceptions and discuss how providers can improve access to inclusive care for transgender and gender diverse patients. Related Content:

Episoder(58)

Two New Treatments for Gonorrhea; one is available now!

Two New Treatments for Gonorrhea; one is available now!

In this episode of the Conversations with CEI, infectious disease specialist Dr. Steven Fine delves into groundbreaking advancements in the treatment of urogenital gonorrhea. The episode highlights th...

12 Jan 15min

PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

On June 18, 2025, the FDA approved Yeztugo, the brand name for subcutaneous lenacapavir, a prescription medication used for the pre-exposure prophylaxis of HIV.  Subcutaneous lenacapavir is administer...

20 Nov 202528min

Keeping an Eye on STIs – Have You Heard of TMVII?

Keeping an Eye on STIs – Have You Heard of TMVII?

This month, host Dr. Marguerite Urban chats with Dr. Jason Zucker, an adult and pediatric infectious diseases physician at Columbia University and the assistant medical director of the New York City H...

13 Nov 202518min

Recap of the 2025 Annual New York State Hepatitis C and Drug User Health Conference

Recap of the 2025 Annual New York State Hepatitis C and Drug User Health Conference

On September 9th, CEI hosted its first in-person conference dedicated to hepatitis C and drug user health. A group of New York State-based clinicians met in Catskill for a full day agenda focused on (...

9 Okt 202527min

Insights from the 13th International AIDS Society Conference on HIV Science

Insights from the 13th International AIDS Society Conference on HIV Science

In this episode of Conversations with CEI, Dr. Steven Fine unpacks some of the latest developments and research presented at the 2025 International AIDS Society (IAS) Conference on HIV Science, held i...

9 Sep 202516min

Evolving Landscape of Geriatric HIV Care

Evolving Landscape of Geriatric HIV Care

The demographics of HIV care are rapidly changing, and with them, the clinical needs of patients aging with HIV. In this episode, host Dr. Tony Urbina, Medical Director for CEI's HIV Primary Care and ...

11 Aug 202527min

Highlights and Perspectives from the 11th Annual NYS Sexual Health Conference

Highlights and Perspectives from the 11th Annual NYS Sexual Health Conference

Live from Canandaigua…it’s the 11th Annual NYS Sexual Health Conference! The CEI Sexual Health Center of Excellence hosted the 11th Annual NYS Sexual Health Conference in-person on Friday May 2, 2025,...

10 Jul 202516min

Xylazine & Medetomidine & Nitazines, Oh My! An Update on New York State’s Drug Supply

Xylazine & Medetomidine & Nitazines, Oh My! An Update on New York State’s Drug Supply

New York drug overdose deaths and death rates are on the decline, but with significant disparities and the current, toxic drug supply is partially to blame. Harmful additives like fentanyl analogues, ...

12 Jun 202529min

Populært innen Fakta

fastlegen
dine-penger-pengeradet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
treningspodden
foreldreradet
jakt-og-fiskepodden
merry-quizmas
dopet
rss-sunn-okonomi
rss-strid-de-norske-borgerkrigene
hverdagspsyken
podme-bio-3
gravid-uke-for-uke
rss-kull
sovnlos
sinnsyn
tomprat-med-gunnar-tjomlid
dypdykk
rss-var-forste-kaffe
fryktlos